Cognition Therapeutics (CGTX) Expected to Announce Quarterly Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Cognition Therapeutics to post earnings of ($0.06) per share and revenue of $5.00 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect Cognition Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Cognition Therapeutics Price Performance

Cognition Therapeutics stock traded up $0.06 during trading hours on Tuesday, hitting $0.95. The stock had a trading volume of 161,238 shares, compared to its average volume of 1,203,310. Cognition Therapeutics has a 1-year low of $0.55 and a 1-year high of $3.83. The stock has a market capitalization of $85.03 million, a price-to-earnings ratio of -3.96 and a beta of 1.78. The stock’s fifty day moving average is $1.14 and its two-hundred day moving average is $1.13.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds have recently modified their holdings of CGTX. Tocqueville Asset Management L.P. raised its holdings in Cognition Therapeutics by 18.5% in the 4th quarter. Tocqueville Asset Management L.P. now owns 192,500 shares of the company’s stock valued at $260,000 after acquiring an additional 30,000 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Cognition Therapeutics by 35.9% during the fourth quarter. Renaissance Technologies LLC now owns 969,513 shares of the company’s stock worth $1,309,000 after purchasing an additional 256,013 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Cognition Therapeutics by 22.6% in the fourth quarter. Geode Capital Management LLC now owns 873,954 shares of the company’s stock valued at $1,180,000 after purchasing an additional 161,227 shares during the period. Alyeska Investment Group L.P. purchased a new stake in shares of Cognition Therapeutics in the third quarter valued at $138,000. Finally, Millennium Management LLC acquired a new position in Cognition Therapeutics in the third quarter valued at $757,000. 43.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CGTX. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Cognition Therapeutics in a research note on Monday, June 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $3.33.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.